Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Durable responses in the updated 2-year follow-up of patients from a single-center with Relapsed/Refractory peripheral T-cell lymphoma treated with golidocitinib

View Full Paper
Ask AI
Bookmark
Share

Authors

CBCasey BermackCPC. ParasBVBryan Valcárcel

Discussion

Loading...

Member takes

Overview

Phase 2 trial reveals improved progression-free survival in patients with relapsed/refractory peripheral T-cell lymphoma treated with golidocitinib.

Key Points

  • To evaluate the efficacy and safety of golidocitinib in patients with relapsed/refractory peripheral T-cell lymphoma.
  • Included patients from a single-arm, multinational, phase 2 trial
  • Administered golidocitinib 150 mg daily until progression
  • Assessed overall response rate, progression-free survival, and overall survival using Kaplan-Meier method.
  • Overall response rate was 53.8% with a median progression-free survival of 37.9 months
  • 2-year overall survival rate was 76.9%
  • Responders exhibited significant phenotypic profiles indicating potential biomarkers for response.

Cite This Study

Bermack et al. (2025) studied this question.

synapsesocial.com/papers/69362f364fa91c937236d2e4https://doi.org/10.1182/blood-2025-5422
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Phase 2 multicenter maintenance study of golidocitinib, A JAK1 selective inhibitor, in patients with peripheral T cell lymphomas after first-line systemic therapy (JACKPOT26)2026 · 2 citations
  2. 2Golidocitinib combined with CHOP in newly-diagnosed peripheral T-cell lymphoma: Preliminary Results from A phase 1/2 clinical trial2025 · 1 citations
  3. 3Golidocitinib combination therapy as first-line treatment in PTCL: Retrospective data from a single centre2025
  4. 4Preliminary efficacy and safety of golidocitinib in relapsed/refractory T cell and NK cell large granular lymphocyte leukemia2025
  5. 5Dual anti-HLH and antitumor efficacy of golidocitinib in relapsed/refractory PTCL-associated hemophagocytic lymphohistiocytosis: A retrospective safety and activity analysis2025